结直肠癌中的循环肿瘤DNA：机遇与挑战
Circulating tumor DNA in colorectal cancer: opportunities and challenges.
作者信息
Bi Feifei, Wang Qiwei, Dong Qian, Wang Yuanhe, Zhang Liqun, Zhang Jingdong
机构信息
Medical Oncology Department of Gastrointestinal Cancer, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute Shenyang, China.
出版信息
Am J Transl Res. 2020 Mar 15;12(3):1044-1055. eCollection 2020.
Abstract
Tumor biopsy is the standard method for cancer diagnosis and provides an important sample for pathological assessment. With the development of precision medicine, liquid biopsies are now an important tool to detect molecular changes and tumor heterogeneity. In recent years, research related to circulating tumor DNA (ctDNA) has intensified due to its non-invasive, convenient, comprehensive, and safety characteristics. Herein, we provide a review describing the clinical applications and prospects of ctDNA in colorectal cancer (CRC) diagnosis, monitoring and prognosis.
摘要
肿瘤活检是癌症诊断的标准方法，为病理评估提供重要样本。随着精准医学的发展，液体活检现已成为检测分子变化和肿瘤异质性的重要工具。近年来，由于循环肿瘤DNA（ctDNA）具有非侵入性、便捷、全面和安全的特点，与之相关的研究不断加强。在此，我们提供一篇综述，描述ctDNA在结直肠癌（CRC）诊断、监测和预后方面的临床应用及前景。
相似文献
1
Circulating tumor DNA in colorectal cancer: opportunities and challenges.结直肠癌中的循环肿瘤DNA：机遇与挑战
Am J Transl Res. 2020 Mar 15;12(3):1044-1055. eCollection 2020.
2
Circulating Tumor Cells Versus Circulating Tumor DNA in Colorectal Cancer: Pros and Cons.结直肠癌中循环肿瘤细胞与循环肿瘤DNA的利弊
Curr Colorectal Cancer Rep. 2016 Jun;12(3):151-161. doi: 10.1007/s11888-016-0320-y. Epub 2016 Apr 7.
3
[Liquid biopsy in colorectal cancer : An overview of ctDNA analysis in tumour diagnostics].[结直肠癌的液体活检：肿瘤诊断中循环肿瘤DNA分析概述]
Pathologe. 2019 Dec;40(Suppl 3):244-251. doi: 10.1007/s00292-019-00698-3.
4
Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.循环肿瘤DNA：癌症液体活检中有前景的生物标志物。
Oncotarget. 2016 Jul 26;7(30):48832-48841. doi: 10.18632/oncotarget.9453.
5
Application of liquid biopsy in precision medicine: opportunities and challenges.液体活检在精准医学中的应用：机遇与挑战。
Front Med. 2017 Dec;11(4):522-527. doi: 10.1007/s11684-017-0526-7. Epub 2017 Jul 25.
6
Role of liquid biopsies in colorectal cancer.液体活检在结直肠癌中的作用。
Curr Probl Cancer. 2018 Nov;42(6):593-600. doi: 10.1016/j.currproblcancer.2018.08.004. Epub 2018 Aug 29.
7
Opportunities, Challenges, and Prospects in Electrochemical Biosensing of Circulating Tumor DNA and its Specific Features.循环肿瘤 DNA 的电化学生物传感的机遇、挑战与前景及其特定特征。
Sensors (Basel). 2019 Aug 30;19(17):3762. doi: 10.3390/s19173762.
8
Assessing the Impact of Circulating Tumor DNA (ctDNA) in Patients With Colorectal Cancer: Separating Fact From Fiction.评估循环肿瘤DNA（ctDNA）对结直肠癌患者的影响：分清虚实。
Front Oncol. 2018 Aug 6;8:297. doi: 10.3389/fonc.2018.00297. eCollection 2018.
9
Circulating Cell-Free DNA and Colorectal Cancer: A Systematic Review.循环游离 DNA 与结直肠癌：系统综述。
Int J Mol Sci. 2018 Oct 26;19(11):3356. doi: 10.3390/ijms19113356.
10
Liquid Biopsy in Colorectal Carcinoma: Clinical Applications and Challenges.结直肠癌的液体活检：临床应用与挑战
Cancers (Basel). 2020 May 27;12(6):1376. doi: 10.3390/cancers12061376.
引用本文的文献
1
Diagnostic methods for pancreatic cancer and their clinical applications (Review).胰腺癌的诊断方法及其临床应用（综述）
Oncol Lett. 2025 May 27;30(1):370. doi: 10.3892/ol.2025.15116. eCollection 2025 Jul.
2
Increased amounts of cell-free DNA released from a culture with a high content of cancer stem cells.从含有高含量癌干细胞的培养物中释放出的游离DNA量增加。
Front Cell Dev Biol. 2025 Mar 28;13:1499936. doi: 10.3389/fcell.2025.1499936. eCollection 2025.
3
Bibliometric analysis of global research trends and prospects on circulating tumor DNA in colorectal cancer.结直肠癌循环肿瘤DNA的全球研究趋势与前景的文献计量分析
Front Oncol. 2024 Nov 15;14:1428942. doi: 10.3389/fonc.2024.1428942. eCollection 2024.
4
Longitudinal detection of somatic mutations in the saliva of head and neck squamous cell carcinoma-affected patients: a pilot study.头颈部鳞状细胞癌患者唾液中体细胞突变的纵向检测：一项试点研究。
Front Oncol. 2024 Nov 1;14:1480302. doi: 10.3389/fonc.2024.1480302. eCollection 2024.
5
Potential value of detection of minimal residual disease in colorectal cancer following radical resection.根治性切除术后结直肠癌微小残留病检测的潜在价值
Chin J Cancer Res. 2024 Aug 30;36(4):442-454. doi: 10.21147/j.issn.1000-9604.2024.04.07.
6
Circulating Nucleic Acids in Colorectal Cancer: Diagnostic and Prognostic Value.结直肠癌循环核酸：诊断和预后价值。
Dis Markers. 2024 Feb 13;2024:9943412. doi: 10.1155/2024/9943412. eCollection 2024.
7
ctDNA as a prognostic biomarker in resectable CLM: Systematic review and meta-analysis.循环肿瘤DNA作为可切除性结直肠癌肝转移预后生物标志物的系统评价与Meta分析
Open Life Sci. 2023 May 19;18(1):20220615. doi: 10.1515/biol-2022-0615. eCollection 2023.
8
Potential prognostic and predictive value of UBE2N, IMPDH1, DYNC1LI1 and HRASLS2 in colorectal cancer stool specimens.UBE2N、IMPDH1、DYNC1LI1和HRASLS2在结直肠癌粪便标本中的潜在预后和预测价值。
Biomed Rep. 2023 Feb 7;18(3):22. doi: 10.3892/br.2023.1604. eCollection 2023 Mar.
9
The Position of Circulating Tumor DNA in the Clinical Management of Colorectal Cancer.循环肿瘤DNA在结直肠癌临床管理中的地位
Cancers (Basel). 2023 Feb 17;15(4):1284. doi: 10.3390/cancers15041284.
10
Liquid biopsy approaches and immunotherapy in colorectal cancer for precision medicine: Are we there yet?结直肠癌精准医学中的液体活检方法与免疫疗法：我们做到了吗？
Front Oncol. 2023 Jan 6;12:1023565. doi: 10.3389/fonc.2022.1023565. eCollection 2022.
本文引用的文献
1
Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer.循环肿瘤 DNA 甲基化谱可实现结直肠癌的早期诊断、预后预测和筛查。
Sci Transl Med. 2020 Jan 1;12(524). doi: 10.1126/scitranslmed.aax7533.
2
Early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer.循环肿瘤 DNA 的早期变化可作为转移性结直肠癌患者对化疗反应的潜在预测指标。
Sci Rep. 2019 Nov 22;9(1):17358. doi: 10.1038/s41598-019-53711-3.
3
Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.循环肿瘤 DNA 分析作为 III 期结肠癌辅助治疗复发风险和获益的标志物。
JAMA Oncol. 2019 Dec 1;5(12):1710-1717. doi: 10.1001/jamaoncol.2019.3616.
4
RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer.在组织检测 RAS 野生型的晚期结直肠癌患者中，游离 DNA 中的 RAS 和 BRAF 突变可预测西妥昔单抗单药治疗的疗效。
Mol Oncol. 2019 Nov;13(11):2361-2374. doi: 10.1002/1878-0261.12550. Epub 2019 Sep 30.
5
Genome-wide cell-free DNA fragmentation in patients with cancer.癌症患者的全基因组游离 DNA 片段化。
Nature. 2019 Jun;570(7761):385-389. doi: 10.1038/s41586-019-1272-6. Epub 2019 May 29.
6
Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial.在潜在可切除转移性结直肠癌中循环肿瘤细胞和循环肿瘤 DNA 的检测：UNICANCER Prodige-14 试验的一项辅助前瞻性研究。
Cells. 2019 May 28;8(6):516. doi: 10.3390/cells8060516.
7
The role of SEPT9 in screening, diagnosis, and recurrence monitoring of colorectal cancer.SEPT9 在结直肠癌的筛查、诊断和复发监测中的作用。
BMC Cancer. 2019 May 14;19(1):450. doi: 10.1186/s12885-019-5663-8.
8
Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer.I至III期结直肠癌患者血浆游离DNA的深度测序分析
JAMA Oncol. 2019 Aug 1;5(8):1124-1131. doi: 10.1001/jamaoncol.2019.0528.
9
Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer.循环肿瘤DNA检测在非转移性结直肠癌术后监测中的预后潜力
JAMA Oncol. 2019 Aug 1;5(8):1118-1123. doi: 10.1001/jamaoncol.2019.0512.
10
Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy.总循环游离 DNA 作为一线奥沙利铂为基础化疗前转移性结直肠癌的预后生物标志物。
Ann Oncol. 2019 Jul 1;30(7):1088-1095. doi: 10.1093/annonc/mdz139.
Zotero 插件